Genomic Health, Inc. (GHDX) Insider Sells $699,090.00 in Stock

Genomic Health, Inc. (NASDAQ:GHDX) insider Laura Leber sold 21,000 shares of the business’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $33.29, for a total transaction of $699,090.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Genomic Health, Inc. (NASDAQ:GHDX) traded up $0.53 on Thursday, hitting $35.95. 120,137 shares of the company were exchanged, compared to its average volume of 185,167. The company has a market capitalization of $1,240.00, a P/E ratio of -276.54 and a beta of 0.65. Genomic Health, Inc. has a twelve month low of $26.37 and a twelve month high of $37.50.

A number of brokerages have weighed in on GHDX. Zacks Investment Research downgraded shares of Genomic Health from a “hold” rating to a “sell” rating in a research note on Tuesday. Barclays reaffirmed a “sell” rating and issued a $28.00 target price on shares of Genomic Health in a research note on Monday. Canaccord Genuity reaffirmed a “buy” rating and issued a $35.00 target price on shares of Genomic Health in a research note on Wednesday, September 27th. Jefferies Group reaffirmed a “hold” rating and issued a $33.00 target price on shares of Genomic Health in a research note on Thursday, September 14th. Finally, William Blair downgraded shares of Genomic Health from an “outperform” rating to a “market perform” rating in a research note on Wednesday, December 20th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $31.71.

Several institutional investors and hedge funds have recently bought and sold shares of GHDX. Cubist Systematic Strategies LLC bought a new stake in shares of Genomic Health during the third quarter worth approximately $138,000. SG Americas Securities LLC raised its stake in shares of Genomic Health by 37.8% during the second quarter. SG Americas Securities LLC now owns 6,122 shares of the medical research company’s stock worth $199,000 after buying an additional 1,679 shares during the last quarter. Legal & General Group Plc raised its stake in shares of Genomic Health by 11.4% during the second quarter. Legal & General Group Plc now owns 6,932 shares of the medical research company’s stock worth $226,000 after buying an additional 710 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of Genomic Health during the third quarter worth approximately $227,000. Finally, Parametric Portfolio Associates LLC raised its stake in shares of Genomic Health by 5.8% during the second quarter. Parametric Portfolio Associates LLC now owns 8,051 shares of the medical research company’s stock worth $262,000 after buying an additional 441 shares during the last quarter. 89.67% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/11/laura-leber-sells-21000-shares-of-genomic-health-inc-ghdx-stock.html.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply